| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.8 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.8 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.8 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | 0.0094 | 0.9 |
| mRNA | HG-6-64-1 | GDSC1000 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.0097 | 0.9 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.0096 | 0.9 |
| mRNA | SU11274 | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |